Monthly Communication Report

Organization:	Cystic Fibrosis Canada/Fibrose kystique Canada
Associated registration:	939590-266824-26
Communication date:	2023-02-16
Posted date:	2023-03-15

Designated Public Office Holders who participated in the communication:	Daniel MacDonald, Director General, Drugs for Rare Diseases Health Canada (HC) Jeff Waring, Chief of Operations, Privy Council Office Privy Council Office (PCO) Footnote1 Michelle Mujoombar, Director, Specialty Pharmaceuticals Health Canada (HC)
Subject Matter of the communication:	Health
Responsible Officer who filed this communication report:	Kelly Grover
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
Footnote1  Indicates new information that was added through a monthly communications return.